| Issue | Title | |
| Vol 2005, No 55 (2005) | Latin America: A Changing Landscape | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Leo Pharma A/S | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 11 (2018) | LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm | Abstract pdf html |
| Sharath Chandra Nakka & Michelle Liu | ||
| Vol 2018, No 9 (2018) | LEO Pharma Signs US$402 M Dermatology Deal with JW Pharmaceutical | Abstract pdf html |
| Michelle Liu & Keval Haria | ||
| Vol 2009, No 10 (2009) | LEO Re-acquires Dermatology Drug Rights from Warner Chilcott | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | LEO Targets Peplin for Skin Cancer Drug | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 72 (2006) | Let Knowledge Flow | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 89 (2007) | Letairis (ambrisentan) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Lexicon Forms Development and Financing Agreement with Symphony Capital | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | LG Life Sciences to Market Thymitaq® in Republic of Korea | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Life Technologies Gets New DNA Sequencing Technology with Ion Torrent Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 11 (2009) | Ligand Acquires Metabasis in Cash and CVR Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | Ligand Acquires Neurogen and Access to Merck Partnership | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 8 (2013) | Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 43 (2004) | Lilly Acquires AME to Optimize its Pipeline Proteins | Abstract pdf |
| Business Review Editor | ||
| Vol 2025, No 1 (2025) | Lilly Acquires Mutant-Selective PI3Kα Inhibitor Programme from Scorpion | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2010, No 9 (2010) | Lilly Acquires Neuroscience Diagnostics Developer Avid Radiopharmaceuticals | Abstract |
| Editorial Team | ||
| Vol 2019, No 5 (2019) | Lilly Adds Centrexion’s Non-Opioid Pain Therapy to Pipeline | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 4 (2019) | Lilly Affirms Immunology Interest with US$605 M ImmuNext Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 75 (2006) | Lilly and Alcon Eye Success with Treatment for Diabetic Retinopathy | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 6 (2017) | Lilly Bolsters Diabetes Pipeline with KeyBioScience Collaboration | Abstract pdf html |
| Natasha Piper | ||
| Vol 2019, No 1 (2019) | Lilly Bolsters Oncology Pipeline with US$8 B Takeover of Loxo Oncology | Abstract pdf html |
| Subham Nandi | ||
| Vol 2024, No 6 (2024) | Lilly Collaborates with QurAlis to Develop ALS Therapies | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2021, No 9 (2021) | Lilly Collaborates with Verge Genomics to Develop ALS Therapies | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2009, No 3 (2009) | Lilly Looks to NeuroSearch to Fill Pipeline Gap | Abstract |
| Taskin Ahmed | ||
| Vol 2021, No 3 (2021) | Lilly Partners with Rigel on RIPK1 Inhibitors | Abstract pdf html |
| Michelle Liu | ||
| Vol 2017, No 9 (2017) | Lilly Pays Nektar US$150 M Upfront to Co-Develop Broad Immunological Therapy | Abstract pdf html |
| Natasha Piper | ||
| Vol 2020, No 1 (2020) | Lilly Pays US$1.1 B for Dermatology-Focused Dermira | Abstract html pdf |
| Michelle Liu | ||
| Vol 2024, No 9 (2024) | Lilly Signs Genetic Medicine Alliances with Haya Therapeutics and Genetics Leap | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 8 (2025) | Lilly Signs US$856 M Licensing Pact with Gate Bioscience to Develop Molecular Gate Therapeutics | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2025, No 6 (2025) | Lilly Signs US$870 M Licensing Pact with Camurus for Long-Acting FluidCrystal® Incretins | Abstract pdf html |
| Naini Anand | ||
| Vol 2023, No 7 (2023) | Lilly to Acquire Diabetes Cell Therapy Partner Sigilon for US$35 M Upfront | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2024, No 7 (2024) | Lilly to Acquire Morphic for US$3.2 B | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2023, No 5 (2023) | Lilly’s Prevail Signs Gene Editing Collaboration with Scribe Therapeutics for Neurological Diseases | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2006, No 71 (2006) | Looking to Academia | Abstract |
| Business Review Editor | ||
| Vol 2021, No 1 (2021) | Loxo Partners with Merus on Bispecific Antibody Therapies | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 10 (2014) | Lumara Health Splits in Two and Finds Buyers in AMAG and Perrigo | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 6 (2014) | Lundbeck Adds to Neurology Portfolio with Chelsea Therapeutics Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 4 (2013) | Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 11 (2011) | Lundbeck and Otsuka Forge US$1.8 B Global CNS Alliance | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 4 (2018) | Lundbeck Bolsters its Parkinson’s Pipeline by Acquiring Prexton Therapeutics | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2019, No 9 (2019) | Lundbeck Expands CNS Franchise with US$2 B Alder Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2008, No 96 (2008) | Lundbeck Gains European Rights for Alzheimer’s Drug | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2009, No 7 (2009) | Lundbeck Hits Acquisition Trail | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 10 (2011) | Lundbeck Invests US$16 M in Proximagen in Strategic CNS Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 10 (2024) | Lundbeck Pays US$2.6 B to Acquire Longboard Pharmaceuticals | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 5 (2019) | Lundbeck Rebuilds Neurology Pipeline with Abide Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 31 (2002) | Lundbeck Strengthens CNS Research Through Acquisition of Synaptic | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 2 (2009) | Lundbeck to Buy US-based Ovation | Abstract html |
| Taskin Ahmed | ||
| Vol 2013, No 2 (2013) | Lycera and Merck & Co. Form Second Autoimmune Disease Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 3 (2011) | Lycera and Merck & Co. to Develop Autoimmune Disease Drugs Targeting Th17 Cells | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 1 (2022) | M&A Activity in 2021 Ends with a Bang | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 4 (2023) | M&A Activity Starts to Pick up in Q2 2023 | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 1 (2013) | MacroGenics Gains Another DART™ Collaborator in Gilead | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 9 (2010) | MacroGenics Signs Deals with Boehringer Ingelheim and Pfizer for DART™ Targets | Abstract |
| Editorial Team | ||
| Vol 2012, No 10 (2012) | MacroGenics Signs Second Regional Option-Based Deal with Servier | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 54 (2004) | Macugen (pegaptanib) | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | Madaus AG | Abstract |
| Business Review Editor | ||
| Vol 2002, No 25 (2002) | Major Pharma is Paying Top Dollar for Late Stage Products to Bolster Flagging Pipelines | Abstract |
| Business Review Editor | ||
| Vol 2008, No 92 (2008) | Making Sense Out of Antisense | Abstract |
| Business Review Editor | ||
| Vol 2015, No 9 (2015) | Mallinckrodt Continues M&A Spree with US$1.325 B Therakos Acquisition | Abstract html |
| Heather Cartwright & Smita Mishra | ||
| Vol 2018, No 1 (2018) | Mallinckrodt Diversifies Portfolio with US$1.2 B Acquisition of Sucampo | Abstract pdf html |
| Subham Nandi | ||
| Vol 2014, No 5 (2014) | Mallinckrodt Expands Speciality Pharmaceuticals Business with US$5.6 B Questcor Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 8 (2019) | Mallinckrodt Signs its First RNAi Deal with Silence Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 9 (2014) | MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Maxygen Licenses Dengue Vaccine Programme to sanofi pasteur | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Maxygen Licenses Interferon Portfolio to Roche | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 74 (2006) | Mayne Pays US$34 M for Rights to SuperGen Oncology | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Mayne Pharma and PLIVA Enter Strategic Biogeneric Partnership for EPO and G-CSF | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Mayne Pharma to market Virulizin® in Brazil | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 46 (2004) | Mayne to Market Paxene® in the EU | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 4 (2010) | MDRNA on Overdrive | Abstract |
| PharmaDeals Analyst | ||
| Vol 2006, No 71 (2006) | Me too | Details jpg |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Meda Acquires North Amercian Rights to Potential Blockbuster from BDSI | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 9 (2014) | Meda Asserts Independence with US$3.1 B Rottapharm Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 25 (2002) | Medarex acquires technology and antibody product development programmes from Corixa | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Medarex's Second Recent US$0.5 B Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Medco Acquires United BioSource for Post-Approval Research Capabilities | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 3 (2012) | Medicago and Mitsubishi Tanabe Pharma Form Vaccines Alliance | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 75 (2006) | Medicure Takes Over US Marketing of Aggrastat#174; | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | MediGene AG | Abstract |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | MedImmune Seeks Portfolio Expansion with Medarex Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | MedImmune to Advance AgonOx’s OX40 Cancer Agonists in Global Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 100 (2008) | Medivation and Pfizer to Partner on Alzheimer’s Drug | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2003, No 40 (2003) | Medivir and Boehringer Ingelheim in HIV Deal | Abstract |
| Business Review Editor | ||
| Vol 2016, No 11 (2016) | Medivir Prioritises R&D by Divesting Mature Biophausia Portfolio | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2006, No 74 (2006) | Medivir Refocuses its Pipeline via Tibotec Deals | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Medtronic Acquires Kyphon for US$3.9 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 4 (2011) | Medtronic and Eli Lilly in Drug-Device Pact for Parkinson’s Disease | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 11 (2012) | Menarini Forms Antibody-Based Drug Alliance with Oxford BioTherapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | Merck & Co Expands Biologics Manufacturing | Abstract |
| Taskin Ahmed | ||
| Vol 2016, No 7 (2016) | Merck & Co Extend Association with Moderna on New Oncology Programme | Abstract pdf html |
| Keshav Mahawar | ||
| Vol 2014, No 8 (2014) | Merck & Co. Accelerates Development of All-Oral HCV Triple-Drug Regimen with Idenix Acquisition | Abstract Untitled |
| Heather Cartwright | ||
| Vol 2017, No 9 (2017) | Merck & Co. Acquires German Start-Up Rigontec with Aim of Advancing Immuno-Oncology Success | Abstract pdf html |
| Natasha Piper | ||
| Vol 2022, No 11 (2022) | Merck & Co. Acquires Imago BioSciences for US$1.35 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2011, No 8 (2011) | Merck & Co. Acquires North American Rights to Cardiome’s Intravenous Vernakalant from Astellas | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 12 (2014) | Merck & Co. Agrees to Buy Cubist in US$9.5 B Deal to Strengthen its Acute Care Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 6 (2011) | Merck & Co. and Hanwha Chemical Partner to Develop a Biosimilar Version of Enbrel® | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 4 (2011) | Merck & Co. Bolsters its Eye Care Franchise with Inspire Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 6 (2019) | Merck & Co. Bolsters Oncology Pipeline with US$773 M Acquisition of Tilos Therapeutics | Abstract pdf html |
| Sharath Chandra Nakka & Michelle Liu | ||
| 1501 - 1600 of 2613 Items | << < 11 12 13 14 15 16 17 18 19 20 > >> | |